Your browser doesn't support javascript.
loading
Angiotensin II-Receptor Inhibition With Candesartan to Prevent Trastuzumab-Related Cardiotoxic Effects in Patients With Early Breast Cancer: A Randomized Clinical Trial.
Boekhout, Annelies H; Gietema, Jourik A; Milojkovic Kerklaan, Bojana; van Werkhoven, Erik D; Altena, Renske; Honkoop, Aafke; Los, Maartje; Smit, Willem M; Nieboer, Peter; Smorenburg, Carolien H; Mandigers, Caroline M P W; van der Wouw, Agnes J; Kessels, Lonneke; van der Velden, Annette W G; Ottevanger, Petronella B; Smilde, Tineke; de Boer, Jaap; van Veldhuisen, Dirk J; Kema, Ido P; de Vries, Elisabeth G E; Schellens, Jan H M.
Afiliación
  • Boekhout AH; Division of Clinical Pharmacology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Gietema JA; Department of Medical Oncology University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
  • Milojkovic Kerklaan B; Division of Clinical Pharmacology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • van Werkhoven ED; Biometrics Department, Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Altena R; Department of Medical Oncology University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
  • Honkoop A; Department of Internal Medicine, Isala Clinics, Zwolle, the Netherlands.
  • Los M; Department of Internal Medicine, Antonius Hospital, Nieuwegein, the Netherlands.
  • Smit WM; Department of Internal Medicine, Medisch Spectrum Twente, Enschede, the Netherlands.
  • Nieboer P; Department of Internal Medicine, Wilhelmina Hospital, Assen, the Netherlands.
  • Smorenburg CH; Department of Internal Medicine, Medical Center Alkmaar, Alkmaar, the Netherlands.
  • Mandigers CM; Department of Internal Medicine, Canisius Wilhemina Hospital, Nijmegen, the Netherlands.
  • van der Wouw AJ; Department of Internal Medicine, VieCuri Medical Center Noord-Limburg, Venlo, the Netherlands.
  • Kessels L; Department of Internal Medicine, Deventer Hospital, Deventer, the Netherlands.
  • van der Velden AW; Department of Internal Medicine, Martini Hospital, Groningen, the Netherlands.
  • Ottevanger PB; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, the Netherlands.
  • Smilde T; Department of Internal Medicine, Jeroen Bosch Hospital, Den Bosch, the Netherlands.
  • de Boer J; Department of Internal Medicine, Hospital de Tjongerschans, Heerenveen, the Netherlands.
  • van Veldhuisen DJ; Department of Cardiology, University Medical Center Groningen, the Netherlands.
  • Kema IP; Department of Laboratory Medicine University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
  • de Vries EG; Department of Medical Oncology University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
  • Schellens JH; Division of Clinical Pharmacology, Netherlands Cancer Institute, Amsterdam, the Netherlands18Department of Pharmaceutical Sciences, Science Faculty Utrecht University, Utrecht, the Netherlands.
JAMA Oncol ; 2(8): 1030-7, 2016 Aug 01.
Article en En | MEDLINE | ID: mdl-27348762
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Tetrazoles / Bencimidazoles / Neoplasias de la Mama / Receptor ErbB-2 / Bloqueadores del Receptor Tipo 1 de Angiotensina II / Cardiotoxicidad / Trastuzumab / Antineoplásicos Tipo de estudio: Clinical_trials / Etiology_studies / Prognostic_studies Límite: Adult / Aged / Female / Humans / Middle aged País/Región como asunto: Europa Idioma: En Revista: JAMA Oncol Año: 2016 Tipo del documento: Article País de afiliación: Países Bajos Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Tetrazoles / Bencimidazoles / Neoplasias de la Mama / Receptor ErbB-2 / Bloqueadores del Receptor Tipo 1 de Angiotensina II / Cardiotoxicidad / Trastuzumab / Antineoplásicos Tipo de estudio: Clinical_trials / Etiology_studies / Prognostic_studies Límite: Adult / Aged / Female / Humans / Middle aged País/Región como asunto: Europa Idioma: En Revista: JAMA Oncol Año: 2016 Tipo del documento: Article País de afiliación: Países Bajos Pais de publicación: Estados Unidos